Kit Orders

Cardiovascular disease biomarker-driven development

Advance cardiovascular development with expert insights on biomarker strategies that streamline cardiovascular clinical trials and support novel treatments for heart disease.

Start a Conversation

Cardiovascular disease (CVD) is a leading cause of mortality worldwide and a key component of the broader cardiometabolic landscape. Its pathophysiology spans myocardial dysfunction, vascular inflammation, dysfunction in lipid metabolism, renal impairment and systemic metabolic dysregulation, all of which can make trial design and patient stratification highly complex. Our biomarker-driven solutions help simplify this complexity into actionable insights for biopharma partners, enabling more precise clinical trials, faster timelines, and a foundation for future label expansion.

Therapeutic area expertise

Deep experience in cardiovascular biomarkers and indications including heart failure, coronary artery disease, peripheral artery disease, stroke, hypertension, dyslipidemia and more

Operational support

An interconnected global lab network, scalable logistics, and proven experience supporting rare disease and mega trials across 175+ studies, 240,000 patients and 60+ countries

Patient-centric solutions

Access to high-risk and underserved populations, decentralized trial capabilities and flexible specimen collection and testing options to improve recruitment and retention

Biomarkers that reflect the full spectrum of cardiovascular disease

Biomarkers enable precise measurement of biological processes and disease progression, helping researchers identify patient subgroups most likely to respond to targeted treatments . By incorporating established biomarkers—such as brain natriuretic peptide (BNP) and troponin for myocardial dysfunction, lipid profiles and Apo-lipoproteins for lipid metabolism, or inflammatory markers like C-reactive protein (CRP) and interleukin 6 (IL-6)—clinical trials can more effectively stratify populations, monitor efficacy and anticipate adverse events.

Our cardiovascular biomarker toolkit and associated cytokine testing capabilities are designed to help you characterize complex disease mechanisms, stratify patients and support regulatory endpoints across a range of indications.

Key biomarkers for cardiovascular therapy development

Group	Biomarkers
Myocardial dysfunction and ischemia	BNP, NT-ProBNP, troponin I/T, CK-MB, myoglobin, soluble ST2, GDF-15, galectin-3, lactate
Lipid metabolism	Lipid profile (Total Cholesterol (TC), LDL-C, HDL-C, Triglycerides, Fatty acids), ApoAI, ApoB, ApoE4, ApoC3, NMR lipoprotein profiling, LP-IR test, Lp(a)
Metabolic markers and adipokines	HbA1C, insulin, adiponectin, ghrelin, leptin
Vascular and endothelial function	E-selectin, P-selectin, VCAM, ICAM-1, PAI-1, MCP-1/CCL2, MPO, ACE
Renal and neurohumoral markers	KIM-1, NGAL, cystatin C, osteopontin, EGF, TGFβ, β2-microglobulin, renin, angiotensin II
Inflammation and cytokines	TNFα, IL-6, IL-18, IFNγ, IL-1β, hsCRP, MCP-1, uric acid, serum amyloid A, GlycA
Oxidative stress and matrix remodeling/coagulation markers	MPO, D-dimer, MMP9, VEGF, TIMP1, PINP, PIIINP, suPAR, von Willebrand factor, fibrinogen, miRNA (exploratory expression), genetic variants

Latest resources for cardiovascular disease

Articles — 30 April Apr 2026

Info Sheets — 23 March Mar 2026

Explore Related Areas

Enhance your drug development programs with Labcorp’s comprehensive solutions and insights across multiple therapeutic areas.

Cardiometabolic Disease Overview
Renal Disease (Nephrology, CKD)
MASH/MASLD & Hepatology
Obesity & Weight Management (GLP-1s, Diabetes)

Managing Your Health

Diseases & Therapeutic Areas

Treatment Modalities & Methods

Scientific Lab Disciplines

Labs

Industries